Jochen Greiner

12PUBLICATIONS
19CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Medical molecular engineering of nucleic acids and proteinsCancer therapy (excl. chemotherapy and radiation therapy)Innate immunityGene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Oct 28, 2025
Different immunotherapeutic combinations enhance specific T cell immune responses against leukemic cells, as well as leukemic progenitor cells, in acute myeloid leukemia.

Jochen Greiner, Patrick J Schuler, Hubert Schrezenmeier

|Oct 26, 2024
Immunotherapeutic Potential of Mutated NPM1 for the Treatment of Acute Myeloid Leukemia.

Jochen Greiner, Eithar Mohamed, Daniel M Fletcher

|Apr 27, 2024
The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma-a randomized, open-label phase III trial of the European mantle cell lymphoma network.

Luca Fischer, Linmiao Jiang, Jan Dürig

|Jun 10, 2023
A Combination of the Immunotherapeutic Drug Anti-Programmed Death 1 with Lenalidomide Enhances Specific T Cell Immune Responses against Acute Myeloid Leukemia Cells.

Barbara-Ann Guinn, Patrick J Schuler, Hubert Schrezenmeier

|Jul 08, 2022
Enhanced stimulation of antigen-specific immune responses against nucleophosmin 1 mutated acute myeloid leukaemia by an anti-programmed death 1 antibody.

Jochen Greiner, Marlies Goetz, Patrick J Schuler

|Mar 25, 2022
Increasing Role of Targeted Immunotherapies in the Treatment of AML.

Jochen Greiner, Marlies Götz, Verena Wais

Pageof 2

Frequent Collaborators

5 joint publications

Barbara-Ann Guinn

3 joint publications

Patrick J Schuler

1 joint publications

Michael Schmitt

1 joint publications

Cornelia Brunner